PharmacyInfoline.com

11/12/2024

All India Pharmaceutical Association Consortium Launches Programme to Empower MSMEs in Pharma Sector

AIPAC launches its first programme to empower MSMEs in the pharmaceutical sector, focusing on skill development, regulatory compliance, and scientific excellence.

11/12/2024

Bio-Techne’s Asuragen Launches High-Sensitivity ESR1 Mutation Monitoring Assay for HR+ Metastatic Breast Cancer Research

Bio-Techne’s Asuragen launches a sensitive ESR1 mutation monitoring assay for HR+ metastatic breast cancer research, enhancing early detection of treatment resistance

11/12/2024

Jupiter Foundation’s ‘My Organ Project’ raises awareness about organ donation, dispels myths, and encourages pledging organs to save lives, fostering a culture of giving in India

Jupiter Foundation’s ‘My Organ Project’ raises awareness about organ donation, dispels myths, and encourages pledging organs to save lives, fostering a culture of giving in India

11/12/2024

FDA Recalls Duloxetine Antidepressant: Carcinogenic Impurities Found in 233,000+ Bottles
The U.S. Food and Drug Administration (FDA) has issued an urgent recall of over 233,003 bottles of duloxetine, a widely prescribed antidepressant, due to the detection of carcinogenic impurities. The recall, announced on November 19, 2024, highlights the presence of N-nitroso-duloxetine, a nitrosamine impurity exceeding the recommended safety limits.

Rising Pharmaceuticals recalls over 233,000 bottles of duloxetine after FDA finds carcinogenic impurity N-nitroso-duloxetine above safe limits. Learn more about risks and alternatives.

11/12/2024

Merck Announces Success of KEYLYNK-001 Trial in Ovarian Cancer Treatment



Merck, known as MSD outside the U.S. and Canada, has achieved a major milestone in cancer research. The pharmaceutical giant announced that its phase 3 KEYLYNK-001 trial has met the primary endpoint of progression-free survival (PFS) for patients with BRCA non-mutated advanced epithelial ovarian cancer. This breakthrough highlights the potential of combining Keytruda (pembrolizumab) and Lynparza (olaparib), with or without bevacizumab, as a first-line treatment.

Merck’s KEYLYNK-001 trial demonstrates significant improvement in progression-free survival (PFS) for BRCA non-mutated advanced ovarian cancer using Keytruda and Lynparza. Explore findings and implications

28/11/2024

Explore the concepts of s*x and gender, including biological s*x, gender identity, and gender expression. Understand how concepts intersect

28/11/2024

Endometriosis, a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, severe pain and infertility

28/11/2024

Ozempic has gained popularity as a weight loss medication, but it's important to understand its potential side effects. common side effects

28/11/2024

Mauna Kea Technologies Cellvizio: A Revolutionary Step in Medical Imaging Mauna Kea Technologies has revolutionized medical imaging with

27/11/2024

Explore the Novavax COVID-19 vaccine, a protein-based vaccine offering an alternative to mRNA and viral vector vaccines. efficacy, safety

26/11/2024

Proposed Bharat FDA (Bharat Food and Drug Administration)

establishment of a Bharat Food and Drug Administration (Bharat FDA) bolster and streamline regulatory processes for nutraceuticals, biologics